BiotechTube

Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent Childhood Acute Myeloid Leukemia

Conditions

Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia

Trial Timeline

Feb 4, 2025 → Jun 30, 2026

NCT ID
NCT06247787

About Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate

Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate is a phase 1 stage product being developed by Geron for Recurrent Childhood Acute Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06247787. Target conditions include Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia.

What happened to similar drugs?

4 of 20 similar drugs in Recurrent Childhood Acute Myeloid Leukemia were approved

Approved (4) Terminated (0) Active (16)
🔄Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
✅Zopapogene imadenovec (Zopa)PrecigenApproved
🔄E7777 9 mcg/kgEisaiPhase 3
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
🔄Chemotherapy + Pembrolizumab + RamucirumabEli LillyPhase 3
🔄Abiraterone Acetate + Bicalutamide + Leuprolide + Prednisone + RelugolixSumitomo PharmaPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06247787Phase 1Recruiting

Competing Products

20 competing products in Recurrent Childhood Acute Myeloid Leukemia

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
KPL-914Kiniksa PharmaceuticalsPhase 2
29
KPL-387Kiniksa PharmaceuticalsPhase 2
36
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
34
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
Zopapogene imadenovec (Zopa)PrecigenApproved
44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
30
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
36
PLX3397Daiichi SankyoPhase 2
27
erlotinib + etoposideAstellas PharmaPhase 2
27
Drug Combination TherapySun PharmaceuticalPhase 2
42
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
Eribulin MesylateEisaiPre-clinical
26
Lenvatinib + EverolimusEisaiPhase 1/2
32
E7090EisaiPhase 2
42